Insider Selling: 10x Genomics (NASDAQ:TXG) Insider Sells 8,283 Shares of Stock

10x Genomics (NASDAQ:TXG) insider Benjamin Hindson sold 8,283 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $157,377.00. Following the sale, the insider owned 432,605 shares of the company’s stock, valued at approximately $8,219,495. This represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

10x Genomics Stock Down 5.3%

Shares of 10x Genomics stock traded down $1.06 during trading hours on Tuesday, hitting $19.07. The company’s stock had a trading volume of 5,111,275 shares, compared to its average volume of 3,246,832. The business has a fifty day moving average of $13.55 and a 200 day moving average of $12.44. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $20.34. The company has a market capitalization of $2.41 billion, a PE ratio of -30.76 and a beta of 2.13.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The firm had revenue of $149.00 million during the quarter, compared to analysts’ expectations of $142.50 million. During the same period in the prior year, the company earned ($0.30) EPS. The firm’s revenue was down 1.7% on a year-over-year basis. 10x Genomics has set its Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on TXG. Canaccord Genuity Group increased their target price on 10x Genomics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. Barclays lifted their price objective on shares of 10x Genomics from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. UBS Group boosted their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 10x Genomics in a report on Monday, November 17th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $14.88.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TXG. CIBC Bancorp USA Inc. acquired a new stake in 10x Genomics in the 3rd quarter worth approximately $134,000. Jacobs Levy Equity Management Inc. raised its position in shares of 10x Genomics by 22.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,947,989 shares of the company’s stock valued at $34,462,000 after purchasing an additional 550,250 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in shares of 10x Genomics by 14.9% in the third quarter. CANADA LIFE ASSURANCE Co now owns 25,365 shares of the company’s stock worth $287,000 after buying an additional 3,296 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of 10x Genomics by 41.0% during the 3rd quarter. XTX Topco Ltd now owns 81,070 shares of the company’s stock worth $948,000 after buying an additional 23,555 shares during the period. Finally, Voleon Capital Management LP grew its stake in 10x Genomics by 73.9% in the 3rd quarter. Voleon Capital Management LP now owns 306,101 shares of the company’s stock valued at $3,578,000 after buying an additional 130,094 shares during the last quarter. 84.68% of the stock is owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.